文献速递肿瘤 PET/CT放射性药物与辐射防护

[68Ga]Ga-FAPI-04与[18F]FDG双示踪剂全身PET/CT及PET/MR成像的临床探索

Clinical Explorations of [68Ga] Ga-FAPI-04 and [18F] FDG Dual-Tracer Total-body PET/CT and PET/MR Imaging.
PubMed 文献 · Semin Nucl Med · 2024-11-02

本文综述了[68Ga]Ga-FAPI-04与[18F]FDG双示踪剂PET/CT和PET/MR成像的临床探索。FAPI与FDG提供互补的生物学信息,双示踪剂临床应用日益增多,但最佳协议仍在研究中。全身PET/CT高灵敏度支持低活度成像和新协议,PET/MR多参数成像提供额外生物学信息,低活度PET/MR成像临床可行性研究结果令人鼓舞。综述讨论了降低辐射暴露和优化工作流程的临床探索,并提出了包括双示踪剂双低活度成像在内的潜在新临床探索方向。

要点

  • FAPI与FDG提供互补生物学信息,双示踪剂成像临床应用日益增多。
  • 全身PET/CT高灵敏度支持低示踪剂活度成像及新双示踪剂协议创建。
  • 低活度PET/MR成像临床可行性研究结果令人鼓舞。

核心结论

  • 综述讨论了降低辐射暴露和优化[68Ga]Ga-FAPI-04与[18F]FDG双示踪剂PET/CT及PET/MR成像工作流程的临床探索。
  • 综述提出了包括双示踪剂双低活度成像在内的[68Ga]Ga-FAPI-04与[18F]FDG双示踪剂全身PET/CT及PET/MR成像潜在新临床探索方向。

研究设计与样本

  • 综述类文章,检索范围原文未报告。

主要发现

  • FAPI与[18F]FDG提供互补的生物学信息,FAPI/FDG双示踪剂成像临床应用近期日益增多。
  • FAPI/FDG双示踪剂PET/CT和PET/MR成像的最佳协议仍在研究中。
  • 全身PET/CT因高灵敏度允许以最低示踪剂活度进行成像,并支持创建新的双示踪剂PET/CT成像协议。
  • PET/MR的多参数MR成像为诊断提供额外的生物学信息。
  • 研究已探索低活度PET/MR成像的临床可行性,结果令人鼓舞。

局限性

  • 全球范围内拥有全身PET/CT先进使用经验并配备PET/MR扫描仪的机构仍很少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fibroblast activation protein inhibitor (FAPI) and [18F]fluorodeoxyglucose ([18F]FDG) provide complementary biological information, and FAPI/FDG dual-tracer imaging clinical application is increasing recently. However, optimal protocols for FAPI/FDG dual-tracer positron emission tomography/computed tomography (PET/CT) and PET/magnetic resonance (PET/MR) imaging are still under investigation. Due to its high sensitivity, total-body PET/CT allows for imaging with minimal tracer activity and supports the creation of new dual-tracer PET/CT imaging protocols. PET/MR, with its multiparametric MR imaging, provides additional biological information for diagnosis. Studies have investigated the clinical feasibility of low-activity PET/MR imaging, yielding promising results. As there are still few institutions in the world that have experience with the advances provided by the use of total-body PET/CT and equipped with a PET/MR scanner, we have discussed the clinical explorations to reduce radiation exposure and optimize workflows for [68Ga]Ga-FAPI-04 and [18F]FDG dual-tracer PET/CT and PET/MR imaging. The review also provides potential new clinical explorations of [68Ga]Ga-FAPI-04 and [18F]FDG dual-tracer total-body PET/CT and PET/MR imaging, including dual-tracer dual-low-activity imaging.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lin Y, Gao H, Zheng J, et al. Clinical Explorations of [68Ga] Ga-FAPI-04 and [18F] FDG Dual-Tracer Total-body PET/CT and PET/MR Imaging. Semin Nucl Med. 2024. PMID: 39489646. doi:10.1053/j.semnuclmed.2024.09.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。